PuSH - Publikationsserver des Helmholtz Zentrums München

Carneiro, S.* ; Müller, J.T.* ; Merkel, O.M.

Targeted molecular therapeutics for pulmonary diseases: Addressing the need for precise drug delivery.

In:. Berlin ; Heidelberg: Springer, 2024. DOI: 10.1007/164_2023_703 (Handb. Exp. Pharmacol.)
DOI PMC
Respiratory diseases are a major concern in public health, impacting a large population worldwide. Despite the availability of therapies that alleviate symptoms, selectively addressing the critical points of pathopathways remains a major challenge. Innovative formulations designed for reaching these targets within the airways, enhanced selectivity, and prolonged therapeutic effects offer promising solutions. To provide insights into the specific medical requirements of chronic respiratory diseases, the initial focus of this chapter is directed on lung physiology, emphasizing the significance of lung barriers. Current treatments involving small molecules and the potential of gene therapy are also discussed. Additionally, we will explore targeting approaches, with a particular emphasis on nanoparticles, comparing targeted and non-targeted formulations for pulmonary administration. Finally, the potential of inhaled sphingolipids in the context of respiratory diseases is briefly discussed, highlighting their promising prospects in the field.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Sammelbandbeitrag/Buchkapitel
Korrespondenzautor
Schlagwörter Gene Therapy ; Inhalation ; Pulmonary Administration ; Sphingolipids ; Targeted Nanoparticles
ISSN (print) / ISBN 0171-2004
Zeitschrift Handbook of Experimental Pharmacology
Verlag Springer
Verlagsort Berlin ; Heidelberg
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Lung Health and Immunity (LHI)